Papers/PMID:33812218
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
Psychiatry research2021The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
berberine — decreases LDL cholesterol
Evidence strength: very limited.Findingreplicated ×1“Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”
Quoted verbatim from The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- berberine 900 mg/day
- Population
- patients with schizophrenia, berberine given as adjunctive treatment
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.2021PMID:3381221810.1016/j.psychres.2021.113899Permalink
berberine — decreases total cholesterol (TC)
Evidence strength: very limited.Findingreplicated ×2“Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”
Quoted verbatim from The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- berberine 900 mg/day
- Population
- patients with schizophrenia, berberine given as adjunctive treatment
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.2021PMID:3381221810.1016/j.psychres.2021.113899Permalink